Humana Inc. (NYSE:HUM) had its target price boosted by stock analysts at Morgan Stanley from $269.00 to $276.00 in a report issued on Thursday. The firm currently has an “overweight” rating on the insurance provider’s stock. Morgan Stanley’s price target would suggest a potential upside of 11.44% from the company’s previous close.

Several other brokerages also recently weighed in on HUM. UBS AG reiterated a “neutral” rating and issued a $250.00 price objective (up from $237.00) on shares of Humana in a research report on Wednesday, August 9th. BidaskClub upgraded shares of Humana from a “sell” rating to a “hold” rating in a research report on Thursday, August 10th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $223.00 price objective (up from $200.00) on shares of Humana in a research report on Thursday, August 3rd. Jefferies Group LLC reiterated a “hold” rating and issued a $257.00 price objective on shares of Humana in a research report on Friday, August 4th. Finally, Deutsche Bank AG lifted their price objective on shares of Humana from $234.00 to $243.00 and gave the company a “hold” rating in a research report on Monday, August 7th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $244.35.

Shares of Humana (HUM) traded up 0.12% on Thursday, hitting $247.66. 737,053 shares of the stock were exchanged. The firm’s 50 day moving average price is $240.60 and its 200 day moving average price is $224.06. Humana has a one year low of $163.50 and a one year high of $255.27. The firm has a market cap of $35.79 billion, a price-to-earnings ratio of 20.37 and a beta of 0.91.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, August 2nd. The insurance provider reported $3.49 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.08 by $0.41. The firm had revenue of $13.53 billion for the quarter, compared to the consensus estimate of $13.61 billion. Humana had a net margin of 3.37% and a return on equity of 15.85%. During the same period last year, the firm posted $2.30 EPS. Equities analysts anticipate that Humana will post $11.55 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This report was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at https://www.americanbankingnews.com/2017/08/17/humana-inc-hum-pt-raised-to-276-00.html.

In other Humana news, CEO Bruce D. Broussard sold 12,000 shares of the firm’s stock in a transaction dated Friday, August 11th. The shares were sold at an average price of $251.88, for a total value of $3,022,560.00. Following the completion of the transaction, the chief executive officer now directly owns 80,086 shares in the company, valued at $20,172,061.68. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Brian P. Leclaire sold 4,971 shares of the firm’s stock in a transaction dated Wednesday, June 28th. The stock was sold at an average price of $240.00, for a total transaction of $1,193,040.00. Following the completion of the transaction, the senior vice president now owns 14,258 shares of the company’s stock, valued at $3,421,920. The disclosure for this sale can be found here. Insiders sold a total of 41,406 shares of company stock worth $10,355,086 in the last ninety days. Corporate insiders own 0.80% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in HUM. Nisa Investment Advisors LLC boosted its position in shares of Humana by 1.2% in the first quarter. Nisa Investment Advisors LLC now owns 49,289 shares of the insurance provider’s stock valued at $10,160,000 after buying an additional 570 shares during the last quarter. Quantitative Systematic Strategies LLC purchased a new position in shares of Humana during the first quarter valued at approximately $375,000. Granite Investment Advisors LLC boosted its position in shares of Humana by 12.1% in the first quarter. Granite Investment Advisors LLC now owns 2,410 shares of the insurance provider’s stock valued at $497,000 after buying an additional 260 shares during the last quarter. Columbus Circle Investors boosted its position in shares of Humana by 97.4% in the first quarter. Columbus Circle Investors now owns 13,623 shares of the insurance provider’s stock valued at $2,808,000 after buying an additional 6,722 shares during the last quarter. Finally, State of Alaska Department of Revenue purchased a new position in shares of Humana during the first quarter valued at approximately $342,000. Institutional investors own 99.13% of the company’s stock.

About Humana

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.